A Study Exploring Sotatercept and Ruxolitinib in MPN-Associated Myelofibrosis and Anemia

Prithviraj Bose, MD, an associate professor in the Department of Leukemia, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses a study exploring sotatercept (ACE-011) alone and in combination with ruxolitinib (Jakafi) in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia. 

Prithviraj Bose, MD, an associate professor in the Department of Leukemia, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses a study exploring sotatercept (ACE-011) alone and in combination with ruxolitinib (Jakafi) in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia.

This single-arm, open-label, phase II trial included 2 cohorts of patients, with one receiving sotatercept alone, and the other receiving sotatercept added to ruxolitinib.